PDL-1

Clinical trials for PDL-1 explained in plain language.

Never miss a new study

Get alerted when new PDL-1 trials appear

Sign up with your email to follow new studies for PDL-1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New triple-drug attack targets hard-to-treat stomach cancer

Disease control Recruiting now

This study tests a new three-drug combination for people with advanced stomach or esophageal cancer that has spread and has specific markers (HER2 and PD-L1). About 80 participants will receive zanidatamab, pembrolizumab, and chemotherapy. The goal is to see if this combination c…

Matched conditions: PDL-1

Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control

Last updated May 07, 2026 18:42 UTC

PDL-1

Get alerted when new PDL-1 trials appear

New triple-drug attack targets hard-to-treat stomach cancer